Fort Lauderdale Mayor Dean Trantalis and Pompano Beach Mayor Rex Hardin, along with CEO Bob Swindell of the Greater Fort Lauderdale Alliance, joined the SKNV executive team and business community leaders for Wednesday evening's grand opening ceremony.
FORT LAUDERDALE, Fla., Nov. 22, 2024 /PRNewswire-PRWeb/ -- SKNV, a leader in dermatologic innovation and custom medications, proudly hosted the grand opening of its expanded 37,500 sq. ft. contiguous manufacturing campus in Fort Lauderdale on Wednesday evening.
The state-of-the-art FDA-Registered 503B Outsourcing Facility is set to bring 100 new jobs to the area and increase production capacity by over 15 times, enabling SKNV to ramp up production and rapidly scale. This expansion reinforces SKNV's commitment to revolutionizing dermatology while contributing to local economic growth.
Elected officials and industry leaders joined the SKNV executive team for a grand opening ceremony on Wednesday, marking this significant milestone in advancing patient-centered and provider-directed dermatological care.
SKNV is considered the most interesting and dynamic life sciences company in South Florida, driving innovation in dermatologic medications while adding hundreds of jobs across a diverse range of pharmaceutical roles, from manufacturing and quality assurance to research and customer success.
"SKNV believes we live in an era where patients seek personalized care, and we're here to make that possible," said Spencer Malkin, CEO of SKNV. "Through this new campus, we're advancing our mission to bring high-quality, customized dermatology medications directly to providers and patients alike. This facility isn't just an expansion; it's a commitment to a faster, more reliable approach to patient care, reducing the barriers of traditional pharmacy models. By increasing our production capacity, we're positioned to meet the rising demand for personalized medications."
Local leaders recognize the facility's impact in driving both economic growth and healthcare innovation:
"Fort Lauderdale is proud to be home to SKNV's expansion of its cutting-edge manufacturing campus," added Mayor Dean Trantalis. "SKNV's commitment to job creation and dermatology advancement resonates deeply with our city's values. This expansion not only helps our local economy but also elevates Fort Lauderdale as a career destination in the manufacturing of topical Rx dermatology solutions, and we're excited to support SKNV's future growth and success."
Bob Swindell, CEO of the Greater Fort Lauderdale Alliance, noted, "SKNV's expansion in Fort Lauderdale further reinforces our area as a center of innovation in pharmaceutical manufacturing and life sciences. We applaud SKNV's repeated investment in the Broward community, which continues to drive economic growth through the addition of high-value jobs."
What Does It Mean to Be FDA-Registered 503B?
SKNV operates as an FDA-Registered 503B Outsourcing Facility, which means it adheres to the highest standards of safety, quality, and compliance under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Unlike 503A Compounding Pharmacies, 503B facilities are regulated and inspected by the FDA, produce medications under strict Current Good Manufacturing Practice (CGMP) requirements, and can manufacture in large batches without requiring patient-specific prescriptions. This allows SKNV to uniquely support dermatology providers with in-office dispensing, help address drug shortages and meet growing demand with consistent quality.
SKNV's Commitment to Economic Growth and Healthcare Innovation:
SKNV's investment in Fort Lauderdale brings not only high-quality jobs to the area but also establishes the city as a center for advanced dermatology solutions and manufacturing.
Empowering Providers with Efficient, Patient-Centered Solutions:
SKNV's model not only enhances patient satisfaction but also streamlines practice workflows, improving office efficiencies and reducing administrative burdens. By equipping dermatology providers with high-quality medications tailored to individual skin needs, SKNV's approach targets conditions such as acne, rosacea, melasma, and alopecia. As a leader in patient-centered, provider-directed care, SKNV bridges the gap between healthcare providers and patients, promoting a new standard of personalized care.
ABOUT SKNV:
SKNV is an innovative pharmacy revolutionizing dermatology across the United States with its customized medication solutions. Focused on empowering providers and delivering customized topical medications for skin conditions like acne, melasma, and rosacea, SKNV redefines prescription care. Utilizing a state-of-the-art FDA-Registered 503B Outsourcing Facility ensures high-quality, tailored formulations that can be made without potentially harmful excipients such as allergens and irritants, for certain patients as determined by dermatology prescribers. SKNV eliminates traditional pharmacy hurdles such as prior authorizations, offering accessible and affordable care that enhances patient satisfaction. Through innovation and a commitment to personalized care, SKNV is setting new standards in dermatological health. For more details about 503B Outsourcing Facilities, visit: https://sknv.com/why-503b/ and about SKNV and its comprehensive list of medications, please visit http://www.sknv.com.
Media Contact
Michele Krohn, Full Circle PR, 727.410.9628, [email protected], https://fullcircle-pr.com
SOURCE SKNV
Share this article